Plasma cell leukemia

A rare and aggressive form of leukemia

Classification
External resources

Plasma cells in a blood smear, characteristic of plasma cell leukemia

Plasma cell leukemia (PCL) is a rare and aggressive form of leukemia characterized by the presence of plasma cells in the peripheral blood. It is considered a variant of multiple myeloma, but it is distinguished by its more aggressive clinical course and poorer prognosis.

Classification

Plasma cell leukemia can be classified into two types:

• Primary plasma cell leukemia: This form occurs de novo, meaning it arises without a prior history of multiple myeloma.
• Secondary plasma cell leukemia: This form develops as a progression from pre-existing multiple myeloma.

Pathophysiology

Plasma cell leukemia is characterized by the proliferation of malignant plasma cells, which are a type of white blood cell responsible for producing antibodies. In PCL, these cells are found in large numbers in the peripheral blood, unlike in multiple myeloma where they are primarily located in the bone marrow.

Clinical Features

Patients with plasma cell leukemia may present with a variety of symptoms, including:

• Anemia
• Thrombocytopenia
• Leukopenia
• Hypercalcemia
• Renal failure
• Bone pain

Diagnosis

The diagnosis of plasma cell leukemia is made based on the presence of more than 20% plasma cells in the peripheral blood or an absolute plasma cell count greater than 2 x 10^9/L. Diagnostic tests may include:

• Complete blood count
• Bone marrow biopsy
• Flow cytometry
• Cytogenetic analysis

Treatment

Treatment for plasma cell leukemia is challenging due to its aggressive nature. Options may include:

• Chemotherapy
• Stem cell transplantation
• Targeted therapy
• Immunotherapy

Prognosis

The prognosis for plasma cell leukemia is generally poor, with a median survival of less than one year. Early diagnosis and aggressive treatment are crucial for improving outcomes.

Related pages

• Multiple myeloma
• Leukemia
• Bone marrow
• White blood cell